title: [Treatment of toxic epidermal necrolysis. Experience with 9 patients with consideration of intravenous immunoglobulin].
abstract: Toxic epidermal necrolysis (TEN) is the maximal variant of severe bullous drug reactions with a high mortality rate of 30-40%. Treatment should be interdisciplinary and is best provided in an intensive care setting. Since no specific therapy has been established, supportive intensive care and topical treatment are of crucial importance. Between 1995 and 2005, nine patients with TEN were treated in the anesthesiology intensive care unit in cooperation with dermatology in the University Hospital of Dresden. All patients initially received corticosteroids and five patients were additionally treated with intravenous immunoglobulins (IVIG). The overall mortality of 33% was underestimated by the SAPS II-Score, whereas it was overestimated by the TEN-specific SCORTEN. In more severely affected patients, other scoring systems in addition to SCORTEN should be used for prediction of prognosis and evaluation of therapy. The mortality rate of our IVIG treated patients was 20% vs. 50% compared to the non-IVIG-group. However, due to the small number of patients and contradictory results in the literature, IVIG cannot be generally recommended for the treatment of TEN, but should be considered in early stages of the disease.
authors.affiliation: Klinik und Poliklinik für Anästhesiologie und Intensivmedizin, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Fetscherstrasse 74, 01307, Dresden. petra.spornraft-ragaller@mailbox.tu-dresden.de
authors.forename: P
authors.initials: P
authors.lastname: Spornraft-Ragaller
authors.forename: H
authors.initials: H
authors.lastname: Theilen
authors.forename: G S
authors.initials: GS
authors.lastname: Gottschlich
authors.forename: M
authors.initials: M
authors.lastname: Ragaller
mesh_terms: D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D003422:Critical Care; D003430:Cross-Sectional Studies; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D015994:Incidence; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010348:Patient Care Team; D011239:Prednisolone / Q000627:therapeutic use; D013262:Stevens-Johnson Syndrome / Q000175:diagnosis / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate
chemical_list: D011239:Prednisolone